CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 568 enrolled
Drug / intervention
KSI-301 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04592419
NCT04592419Phase 3Completed

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)

Kodiak Sciences Inc·interventional·Posted Oct 19, 2020·Updated Jun 26, 2024

In Brief

A Phase 3 clinical trial evaluating KSI-301, Aflibercept, and 1 other intervention for Macular Edema and Retinal Vein Occlusion. Completed, enrolled 568 participants across 141 sites in 12 countries.

Detailed Summary

This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCzechia, France, Germany, Hungary, Israel, Italy, Latvia, Poland, Puerto Rico, Slovakia, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedOct 19, 2020
Enrollment StartSep 25, 2020
Primary CompletionJun 10, 2022
Study CompletionJan 19, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.7 years ago

Interventions

KSI-301drug

Intravitreal Injection

Afliberceptdrug

Intravitreal Injection

Sham Procedureother

The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.